Long-Term Vitamin D Supplementation and the Effects on Recurrence and Metabolic Status of Cervical Intraepithelial Neoplasia Grade 2 or 3: A Randomized, Double-Blind, Placebo-Controlled Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

This study was conducted to evaluate the effects of vitamin D supplementation on the recurrence and metabolic status of patients with cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3).

Who Took Part

The study group was 58 women.

PubMed indexes the participants as adults and middle-aged adults, women only.

This randomized, double-blind, placebo-controlled trial was carried out among 58 women diagnosed with CIN2/3.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the women and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Antioxidants, C-Reactive Protein, Cholecalciferol, Dietary Supplements, Inflammation, Insulin Resistance and Metabolome.

Author keywords: Cervical intraepithelial neoplasia grade 2 or 3, Metabolic profiles, Recurrence, Supplementation and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 58 women.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Annals of nutrition & metabolism), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.